News
Asarina Pharma AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB. The Company has entered into an...
Asarina Pharma updates on partnering and financials
2023-11-16 08:33
Stockholm, 16 November 2023. Asarina Pharma AB (publ., “Asarina” or “the Company”) today provides an update on its partnering activities...
Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)
2023-08-23 08:30
(Stockholm, 23 August 2023) Asarina Pharma today releases its First Half-Year Report for 2023. In addition to the financial statements for H1/2023, the...
Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders
2023-05-23 09:02
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in...
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
2023-05-22 11:15
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...
The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...
Asarina Pharma AB (publ) releases Annual Report 2022
2023-04-28 20:30
The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research and Development: This year, Asarina’s...
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)
2023-04-18 10:39
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate...
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome
2023-04-01 14:20
THE STUDY: This was an open label, dual center, add-on study, randomizing 28 Tourette Syndrome patients, 20 males/8 females, 3 adolescents/25 adults between...
Asarina Pharma AB (publ) releases Year-End Report 2022
2023-02-27 08:30
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of...